Health
FDA approves Gilead's daily HIV pill Bixlenvo to simplify treatment regimens
The combination tablet offers a single-pill daily option for adults with suppressed virus who face drug resistance or rely on complex multi-pill schedules.
The short version
- The FDA approved Bixlenvo, a once-daily combination of bictegravir and lenacapavir developed by Gilead Sciences for HIV-1 treatment in adults with suppressed virus.
- The treatment targets patients who require complex regimens due to drug resistance, side effects, or drug interactions, as well as those seeking to switch daily regimens.
- The list price is set at $4,595 for a 30-day supply prior to discounts or assistance programs.
Key facts
- The U.S. Food and Drug Administration approved Gilead's Bixlenvo, combining bictegravir and lenacapavir into a single daily tablet.[CNBC]
- The drug is indicated for adults with suppressed HIV who currently require complex multi-pill regimens or want to switch treatments.[CNBC]
- Gilead estimates that patients unable to use previously existing single-tablet options represent 5% or more of U.S. individuals living with HIV.[CNBC]
- The approval was supported by two Phase 3 trials, including ARTISTRY-1, where Bixlenvo maintained viral suppression at 48 weeks with common side effects of headache, nausea, and diarrhea.[CNBC]
- The 30-day list price for Bixlenvo is $4,595 before discounts, rebates, or patient financial support programs.[CNBC]
What remains uncertain
- The real-world uptake among eligible patients and the final out-of-pocket costs after insurance, co-pay assistance, and rebates remain to be seen.[CNBC]